Universal genomic screening for cardiovascular disease

MultiplAI is a proud alumni of the Illumina Accelerator programme.

We're making cardiovascular screening possible for anyone on earth

MultiplAI is developing a ground-breaking RNA-based, AI-driven affordable diagnostic screening enabling a universal screening for cardiovascular and other complex diseases through a whole blood biopsy.

The challenge we choose to face

Cardiovascular diseases are the leading cause of mortality globally, responsible for almost 18 million deaths per year.

Today, diagnostics are often inaccurate and time-consuming. General practitioners still rely on single biochemical markers such as cholesterol and blood pressure which can fail to recognise the signs of increased risk of suffering a major cardiovascular event. In turn, late diagnosis and inadequate prognosis decrease the chances for successful intervention with primary cardiovascular preventive measures, ultimately creating financial and psychological strain for the patient, their families and their doctors.

We want to change this by making routine and frequent screening for cardiovascular diseases possible for anyone on earth.

Image of. RNA

Our solution

We offer a whole blood screening test using RNA Sequencing and Artificial Intelligence to detect any complex diseases, including cardiovascular disorders and cancer.

Rather than searching for a single molecule that identifies a cardiovascular risk, our test identifies molecular variances in the blood that indicate an increased risk of a cardiovascular event.  Imagine measuring all blood RNA changes that a cardiac risk factor may induce at the same time: A powerful, deep and accurate superbiomarker.

This gives MultiplAI the power to:

  • Accuracy: our approach brings precision medicine to cardiovascular and other complex diseases as has been done with DNA for cancer
  • Simplified results: less confusing or ambiguous results when comparedto existing cardiac screening methods
  • Timely intervention: allows more timely and successful intervention to prevent heart attack or stroke based on evidence not previously seen
  • Universal access: our use of a simple whole blood biopsy and the exponentially decreasing costs of sequencing makes CVD screening affordable and widely accessible to virtually anyone one in the world
  • Improved treatment efficacy assessment: provides the ability toassess and adjust treatment regimens with more confidence

Timing is everything

MultiplAI brings together maturing artificial intelligence algorithms, cost-effective sequencing and remote medicine to detect cardiovascular and other complex diseases and better establish prognosis based on the biological substrate.

It’s time to imagine modern universal remote screening for cardiovascular diseases.

Introducing the

MultiplAI
Superbiomarker

With advances in RNA sequencing, bioinformatic processing and deep learning, we now have the power to measure many biomarkers in the blood.

Our patented RNAseq data transformation process makes it possible to represent the incredible complexity of RNA in highly efficient formats ideal for algorithmic analysis.

Superbiomarker

Our team

Santiago Miriuka, MD MSc PhD

Co-Founder, CEO. CTO

Medical Doctor with 20+ years in
clinical cardiology. Director of a basic
and translational lab working on
cutting-edge cellular and molecular
biology. Data scientist and coder
looking to innovate in medicine.

Carlos Luzzani - Co-Founder and CSO

Charlie Luzzani

Co-Founder, CSO, CPO

Molecular biologist and biotech
specialist with experience
co-founding a bioprinting startup
(WeBio). Investigator at
FLENI-CONICET with 20
peer-reviewed publications.

Mark Ramondt - Co-founder and  CFO

Mark Ramondt

Co-Founder, COO, CFO

Serial entrepreneur, angel investor
and advisor to startups with 25+
years of corporate finance and
open innovation experience.

Meg Samek-Smith

President of US Operations

Rosana Paggio - Head of clinical operations

Rosana Poggio

Head of Medical Affairs

Alejandro La Greca.- Biofinformatics engineer

Alejandro La Greca

Bioinformatics Engineer

María Olivera - Clinical coordinator

María Olivera

Clinical Ops Manager

Cluadia

Claudia Solari

Lab Technician

Pat Rickert

Engineering

Florencia De Lillo

Bioinformatics Analyst

Alan M. Möbbs

Bioinformatic Analyst

Estefania Mancini

Sr Bioinformatics Manager

Steven Ramondt - Marketing and communications

Steven Ramondt

Marketing & Communications

Advisors

Nir Ayalon, Advisor

Nir Ayalon

Tel Aviv, Israel

Serial entrepreneur and
computer scientist with contacts
in Europe and Israel, and expertise
in data science, engineering and
data privacy.

Carl Cook - Advisor

Carl Cook

Cambridge, MA, USA

Senior pharmaceutical executive
based in Boston with 20+ years of
experience in clinical oncology and
precision medicine.

Uday Phadke

Cambridge, UK

A serial entrepreneur and part-timeacademic based in Cambridge UK.He is the originator of the TripleChasm Approach, which challengescurrent dogma about how innovationsare commercialised.

Our partners

Contact us

For more information and presentation of our offering, please contact us.

Thank you for contacting us. We will be respond to your inquiry as soon as possible.
Oops! Something went wrong while submitting the form.